Drug Information for Oral Medications for the Treatment of Mild-to-Moderate COVID-19, Paxlovid (Nirmatrelvir-Ritonavir) and Molnupiravir (Lagevrio), Available on ApoThera Clinical Decision Support Mobile Application
Drug Info: ApoThera Drug Disease Clinical Support App
Molnupiravir (Lagevrio)
– 800 mg (four 200-mg capsules) by mouth every 12 hours x 5 days
– Treatment should be initiated within 5 days of symptom onset
Patient Selection
Use limited to individuals who meet the following criteria:
– Age ≥ 18 years
– Have a positive result of direct SARS-CoV-2 viral testing
– Within 5 days of symptom onset at time of treatment
– At high risk for progression to severe COVID-19, including hospitalization
and death
– Not hospitalized due to COVID-19
Missed Dose (<10 hours)
– Take missed dose as soon as possible, and resume normal dosing schedule
Missed Dose >10 hours
– Skip dose, and take the next dose at the regularly scheduled time
– Do not double dose to make up for missed dose
Contraception
– Females of childbearing potential: Use a reliable method of contraception correctly and consistently, as applicable during treatment and for 4 days after final dose
– Males with partners of childbearing potential: Use a reliable method of contraception correctly and consistently during treatment and for at least 3 months after final dose; risk beyond 3 months after last dose is unknown; studies on the risks >3 months are ongoing
Limitations of Use
– Not authorized for use in patients aged <18 years
– Not authorized for initiation of treatment in patients requiring hospitalization due to COVID-19
– Not authorized for use for >5 consecutive days
– Not authorized for pre-exposure or post-exposure prophylaxis for prevention of COVID-19
